Companies Cryptocurrencies
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
Exchange: NasdaqGS
IPO Date: 24/05/2018
CEO: Mr. Sanjiv Patel
Biotechnology Healthcare 🔗
  • KNSA
  • 8.35
  • 578452096
    market cap
  • 0.13000011
If you bought

shares of Kiniksa Pharmaceuticals Ltd (KNSA) on
You would have made
Old Price $12 Current Price $12

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The firm is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases. The Company’s programs include Rilonacept, which is a protein for inhibiting interleukin-1 alpha and interleukin-1beta; Mavrilimumab, is a monoclonal antibody that antagonizes the signaling of granulocyte macrophage colony stimulating factor, or GM-CSF; KPL-716, is a monoclonal antibody that simultaneously inhibits the signaling of the cytokines interleukin-31, or IL-31, and oncostatin M, or OSM, by targeting their common receptor subunit, oncostatin M receptor beta, or OSMR beta; KPL-045 is a monoclonal antibody inhibitor of the CD30/CD30L interaction, a T-cell co-stimulatory receptor involved in activated T-memory cell function, and KPL-404, is a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity.

Address: Clarendon House 2 Church Street Hamilton HM 11

Stay updated.